<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04062448</url>
  </required_header>
  <id_info>
    <org_study_id>CR108666</org_study_id>
    <secondary_id>54179060WAL2002</secondary_id>
    <nct_id>NCT04062448</nct_id>
  </id_info>
  <brief_title>A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)</brief_title>
  <official_title>Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Combination With Rituximab, in Japanese Patients With Waldenstrom's Macroglobulinemia (WM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate overall response rate (ORR) by Independent Review&#xD;
      Committee (IRC) assessment, when combined with rituximab in Japanese participants with&#xD;
      treatment naïve or relapsed/refractory Waldenstrom's Macroglobulinemia (WM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Actual">August 24, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) - Assessed by Independent Review Committee (IRC)</measure>
    <time_frame>Up to 3.7 years</time_frame>
    <description>The ORR is defined as the percentage of participants with complete response (CR), very good partial response (VGPR) or partial response (PR) by IRC assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 3.7 years</time_frame>
    <description>PFS is defined as duration from the date of initial dose of ibrutinib to the date of disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Ibrutinib and its Metabolite PCI-45227</measure>
    <time_frame>Day 1 of Week 4</time_frame>
    <description>Plasma concentration of ibrutinib and its metabolite PCI-45227 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic Biomarkers Relative to Disease and/or Treatment</measure>
    <time_frame>Predose (Week 1)</time_frame>
    <description>Blood samples will be collected for biomarker analysis that may include myeloid differentiation primary response gene 88 (MYD88), and C-X-C chemokine receptor type 4 (CXCR-4), thought to be prognostic of disease and/or treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to 3.7 years</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Ibrutinib + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Ibrutinib 420 mg will be administered orally.</description>
    <arm_group_label>Ibrutinib + Rituximab</arm_group_label>
    <other_name>PCI-32765</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m^2 will be administered intravenously.</description>
    <arm_group_label>Ibrutinib + Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia (WM) in accordance&#xD;
             with the consensus panel of the second International Workshop on Waldenstrom's&#xD;
             Macroglobulinemia (IWWM)&#xD;
&#xD;
          -  Japanese participants with treatment naïve or relapsed/refractory WM&#xD;
&#xD;
          -  Measurable disease defined as serum monoclonal immunoglobulin M (IgM) greater than (&gt;)&#xD;
             0.5 gram per deciliter (g/dL)&#xD;
&#xD;
          -  Symptomatic disease, requiring treatment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to&#xD;
             (&lt;=) 2&#xD;
&#xD;
          -  Hematology and biochemical values within protocol-defined limits&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative serum pregnancy&#xD;
             test at screening and agree to use highly effective methods of contraception while&#xD;
             taking study drug. Women of childbearing potential must be practicing a highly&#xD;
             effective, preferably user independent method of birth control during treatment with&#xD;
             any drug in this study and for up to 12 months after the last dose of rituximab, 1&#xD;
             month after last dose of ibrutinib. Male participants must use an effective barrier&#xD;
             method of contraception during the study and after receiving the last dose of&#xD;
             ibrutinib, and for up to 12 months after last dose of rituximab if sexually active&#xD;
             with a female of childbearing potential&#xD;
&#xD;
          -  Must sign an informed consent form (ICF) indicating that he or she understands the&#xD;
             purpose of, and procedures required for, the study and is willing to participate in&#xD;
             the study. Participants must be willing and able to adhere to the prohibitions and&#xD;
             restrictions specified in this protocol&#xD;
&#xD;
          -  Must be willing and able to adhere to the lifestyle restrictions specified in this&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Involvement of the central nervous system by WM&#xD;
&#xD;
          -  Prior exposure to ibrutinib or other Bruton's Tyrosine Kinase (BTK) inhibitors&#xD;
&#xD;
          -  Rituximab treatment within the last 12 months before the first dose of study&#xD;
             intervention&#xD;
&#xD;
          -  Received any WM-related therapy &lt;=30 days prior to first administration of study&#xD;
             treatment&#xD;
&#xD;
          -  Plasmapheresis less than (&lt;) 35 days prior to the initiation of study drug, except&#xD;
             when at least one serum IgM central assessment was performed during the screening&#xD;
             period and was &gt;35 days from the most recent plasmapheresis procedure&#xD;
&#xD;
          -  History of other malignancies&#xD;
&#xD;
          -  Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug&#xD;
&#xD;
          -  Infection requiring systemic treatment that was completed &lt;=14 days before the first&#xD;
             dose of study drug&#xD;
&#xD;
          -  Currently active, clinically significant Child-Pugh Class B or C hepatic impairment&#xD;
&#xD;
          -  Inability or difficulty swallowing capsules, malabsorption syndrome, or any disease or&#xD;
             medical condition significantly affecting gastrointestinal function&#xD;
&#xD;
          -  Stroke or intracranial hemorrhage within 12 months prior to enrollment&#xD;
&#xD;
          -  Currently active, clinically significant cardiovascular disease&#xD;
&#xD;
          -  Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor&#xD;
&#xD;
          -  Infection with human immunodeficiency virus (HIV) or active infection with hepatitis B&#xD;
             or hepatitis C virus&#xD;
&#xD;
          -  Major surgery within 4 weeks of first dose of study drug&#xD;
&#xD;
          -  Lactating or pregnant&#xD;
&#xD;
          -  Male participants who plan to father a child while enrolled in this study or within 3&#xD;
             months after the last dose of ibrutinib, and within 12 months after last dose of&#xD;
             rituximab&#xD;
&#xD;
          -  Any contraindication to ibrutinib or rituximab including hypersensitivity to the&#xD;
             active substance or to any of the excipients of ibrutinib or rituximab per local&#xD;
             prescribing information&#xD;
&#xD;
          -  Received an investigational intervention (including investigational vaccines) or used&#xD;
             an invasive investigational medical device within 4 weeks before the planned first&#xD;
             dose of study intervention or is currently enrolled in an investigational study&#xD;
&#xD;
          -  Any condition for which, in the opinion of the investigator, participation would not&#xD;
             be in the best interest of the participant (eg [for example], compromise the&#xD;
             wellbeing) or that could prevent, limit, or confound the protocol-specified&#xD;
             assessments&#xD;
&#xD;
          -  Employee of the investigator or study site, with direct involvement in the proposed&#xD;
             study or other studies under the direction of that investigator or study site, as well&#xD;
             as family members of the employees or the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K., Japan Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kameda General Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>296-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-Ku</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kumamoto Medical Center</name>
      <address>
        <city>Kumamoto-City</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuyama Red Cross Hospital</name>
      <address>
        <city>Matsuyama-City</city>
        <zip>790-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya-City</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka-City</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-City</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Disaster Medical Center</name>
      <address>
        <city>Tachikawa</city>
        <zip>190-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba-City</city>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

